» Articles » PMID: 30993766

Long Noncoding RNA HOXA-AS2 Regulates the Expression of SCN3A by Sponging MiR-106a in Breast Cancer

Overview
Journal J Cell Biochem
Date 2019 Apr 18
PMID 30993766
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the most commonly diagnosed cancer that affects women worldwide. This study aimed to investigate the competing endogenous RNAs (ceRNAs) mechanism in breast cancer. Microarray data were downloaded from the University of California Santa Cruz (UCSC) Xena database. The limma package was used to screen the differentially expressed messenger RNAs (DEMs) and differentially expressed long noncoding RNAs (DELs). Subsequently, functional analysis was performed using DAVID tool. After constructing the protein-protein interaction (PPI) network, we identified the major gene modules using the Cytoscape software. Univariate survival analysis in the survival package was performed. Finally, the ceRNA regulatory network was constructed to identify the critical genes. A total of 1380 DEMs and 345 DELs were identified in breast cancer samples compared with normal samples. Functional enrichment analysis showed that DEMs were mainly involved in cell division, and cell cycle. We screened four major gene modules and identified the hub nodes in these functional modules. Several DEMs (including FABP7, C4BPA, and LAMB3) and three long noncoding RNAs (lncRNAs) (LINC00092, SLC26A4.AS1, and COLCA1) exhibited significant correlation with patients' survival outcomes. In the ceRNA network, the lncRNA HOXA-AS2 regulated the expression level of SCN3A by interacting with hsa-miR-106a-5p. Thus, our study investigated the ceRNA mechanism in breast cancer. The results showed that lncRNA HOXA-AS2 might modulate the expression of SCN3A by sponging miR-106a in breast cancer.

Citing Articles

LncRNA-MALAT1 promotes triple-negative breast cancer progression and function as ceRNA to target REEP5 by sponging miR-106a-5p.

Yang Q, Fu Y, Feng W, Mao J, Xu N, Liu Q Eur J Med Res. 2025; 30(1):159.

PMID: 40059235 PMC: 11892299. DOI: 10.1186/s40001-025-02420-x.


Discovery of a Novel Shared Variant Among Gene and lncRNA at Chromosome 20q13.33 in Familial Progressive Myoclonus Epilepsy.

Chaudhari S, Acharya L, Jasti D, Ware A, Gorthi S, Satyamoorthy K Int J Genomics. 2024; 2024:7518528.

PMID: 39156922 PMC: 11330336. DOI: 10.1155/2024/7518528.


LncRNA HOXA‑AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR‑372.

Wang Y, Shao W Oncol Lett. 2024; 28(2):394.

PMID: 38966577 PMC: 11223025. DOI: 10.3892/ol.2024.14527.


LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis.

Xiao T, Yan A, Tan L, Zhu H, Gao W Oncol Lett. 2024; 27(5):226.

PMID: 38586205 PMC: 10996033. DOI: 10.3892/ol.2024.14359.


Role of HOXA1-4 in the development of genetic and malignant diseases.

Wang L, Sun H, Cao L, Wang J Biomark Res. 2024; 12(1):18.

PMID: 38311789 PMC: 10840290. DOI: 10.1186/s40364-024-00569-x.